insights

COVID-19 Vaccine Updates and Latest Information

Join us for IFM's June 22nd Webinar "IFM COVID-19 Update: Fatigue, Immunomodulation, and PASC" Register Now

In the May  webinar, IFM’s COVID-19 Update: Cardiac, Vascular, and Pulmonary Complications of Post-acute Sequelae of SARS-CoV-2 (PASC), members of the IFM COVID-19 task force, Robert Luby, MD; Patrick Hanaway, MD; and Joel Evans, MD, along with guest presenters, focused on the impacts on the cardiac, vascular, and pulmonary systems. The presenters also shared the latest updates on COVID-19 vaccines and addressed questions and concerns surrounding them.

The recording of this webinar, along with the webinars for February, March, and April, are available below. They are part of a monthly series updating practitioners about the latest medical research on mitigating SARS-CoV-2 infection and addressing Post-Acute Sequelae of SARS-CoV-2 (PASC) as a component of IFM’s Resistance, Resilience, and Recovery: Patient Care in a Pandemic online course.

May 2021
March 2021
MARCH TRANSCRIPT
February 2021
FEBRUARY TRANSCRIPT

As discussed by the panelists, in order to properly assess each vaccine, IFM has created this informational dashboard for each approved vaccine, as well as those in phase 3 clinical trials. We continue to monitor outcomes data for each vaccine after its initial release and will update this dashboard accordingly.

Click on table to zoom

References

  1. US Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers): emergency use authorization (EUA) of the Pfizer-Biontech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Revised January 2021. Accessed February 12, 2021. https://www.fda.gov/media/144413/download
  2. Centers for Disease Control and Prevention. COVID-19 vaccinations in the United States. Updated May 12, 2021. Accessed May 12, 2021. https://covid.cdc.gov/covid-data-tracker/#vaccinations
  3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
  4. Jenco, M. AAP, CDC recommend COVID-19 vaccine for ages 12 and older. AAP News and Journals. Published May 12, 2021. Accessed May 13, 2021. https://www.aappublications.org/news/2021/05/12/cdc-aap-pfizer-covid-vaccine-teens-051221
  5. Perez JL. COVID-19 vaccine BNT162b2: Safety, immunogenicity, and efficacy in subjects 12-15 years-old. Centers for Disease Control and Prevention. Published May 12, 2021. Accessed May 13, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/02-COVID-Perez-508.pdf
  6. US Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers) emergency use authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Revised December 2020. Accessed February 12, 2021. https://www.fda.gov/media/144637/download
  7. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
  8. US Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee meeting February 26, 2021: FDA briefing document Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. Revised February 26, 2021. Accessed February 28, 2021. https://www.fda.gov/media/146217/download
  9. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med. Published online April 21, 2021. doi:10.1056/NEJMoa2101544
  10. Medicines & Healthcare Products Regulatory Agency. Information for healthcare professionals on COVID-19 vaccine AstraZeneca. Updated February 23, 2021. Accessed March 12, 2021. https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-healthcare-professionals-on-covid-19-vaccine-astrazeneca
  11. European Medicines Agency. EMA recommends COVID-19 vaccine AstraZeneca for authorisation in the EU. Updated January 29, 2021. Accessed March 12, 2021. https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu#:~:text=COVID%2D19%20Vaccine%20AstraZeneca%20is,Commission%20on%2029%20January%202021.&text=This%20is%20the%20third%20COVID,EMA%20has%20recommended%20for%20authorisation.
  12. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK [published correction appears in Lancet. 2021; 397(10269):98]. Lancet. 2021;397(10269):99-111. doi:10.1016/S0140-6736(20)32661-1
  13. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-681. doi:10.1016/S0140-6736(21)00234-8
  14. Novavax. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK Phase 3 trial. Published January 28, 2021. Accessed May 13, 2021. https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3
  15. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
  16. Mahase E. COVID-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows. BMJ. 2020;371:m4826. doi:10.1136/bmj.m4826
  17. Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397(10277):875-877. doi:10.1016/S0140-6736(21)00448-7
  18. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-1829. doi:10.1016/S0140-6736(21)00947-8
  19. Levine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021;27(5):790-792. doi:10.1038/s41591-021-01316-7
  20. Pfizer. Pfizer and BioNTech confirm high efficacy and no serious safety concerns through up to six months following second dose in updated topline analysis of landmark COVID-19 vaccine study. Updated April 1, 2021, Accessed April 15, 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious
  21. Centers for Disease Control and Prevention. Science brief: Background rationale and evidence for public recommendations for fully vaccinated people. Updated March 8, 2021. Accessed March 16, 2021. https://www.cdc.gov/coronavirus/2019-ncov/more/fully-vaccinated-people.html#ref29
  22. Parry HM, Tut G, Faustini S, et al. BNT162b2 vaccination in people over 80 years of age induces strong humoral immune responses with cross neutralization of P.1 Brazilian variant. Updated March 31, 2021. Accessed April 15, 2021. doi:10.2139/ssrn.3816840
  23. Liu Y, Liu J, Xia H, et al. BNT162b2-elicited neutralization against new SARS-CoV-2 spike variants. N Engl J Med. Published online May 12, 2021. doi:10.1056/NEJMc2106083
  24. Centers for Disease Control and Prevention. The Vaccine Adverse Reporting System (VAERS) results. Accessed February 12, 2021. https://wonder.cdc.gov/vaers.html
  25. Centers for Disease Control and Prevention. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020. Published January 15, 2021, Accessed February 28, 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm?s_cid=mm7002e1_w
  26. Centers for Disease Control and Prevention. Vaccine considerations for people with underlying medical conditions. Updated December 29, 2020. Accessed February 12, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/underlying-conditions.html
  27. US Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine emergency use authorization review memorandum. Published November 20, 2020. Accessed February 12, 2021. https://www.fda.gov/media/144416/download
  28. Thompson MG, Burgess JL, Naleway Al, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV2 infection among health care personnel, first responders, and other essential and frontline workers – eight U.S. locations, December 2020 – March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500. doi:10.15585/mmwr.mm7013e3
  29. Wu K, Werner AP, Koch M, et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med. 2021;384(15):1468-1470. doi:10.1056/NEJMc2102179
  30. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020–January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(4):125-129. doi:10.15585/mmwr.mm7004e1
  31. Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine. N Engl J Med. 2021;384(19):1824-1835. doi:10.1056/NEJMoa2034201
  32. Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. Published online April 14, 2021. doi:10.1056/NEJMc2105869
  33. American Society of Hematology. Thrombosis with thrombocytopenia syndrome (also termed vaccine-induced thrombotic thrombocytopenia). Updated April 25, 2021. Accessed April 26, 2021. https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia
  34. Shimabukuro T; CDC COVID-19 Vaccine Task Force. Update: thrombosis with thrombocytopenia syndrome (TTS) following COVID-19 vaccination. Advisory committee on immunization practices (ACIP). Centers for Disease Control and Prevention. Published May 12, 2021. Accessed May 13, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/07-COVID-Shimabukuro-508.pdf
  35. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881-891. doi:10.1016/S0140-6736(21)00432-3
  36. Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant. N Engl J Med. Published online March 16, 2021. doi:10.1056/NEJMoa2102214
  37. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72-74. doi:10.1016/S0140-6736(20)32623-4
  38. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. Published online April 9, 2021. doi:10.1056/NEJMoa2104840
  39. European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. Updated April 7, 2021. Accessed April 15, 2021. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood
  40. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 COVID-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1899-1909. doi:10.1056/NEJMoa2103055
  41. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine – United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1922-1924. doi:10.15585/mmwr.mm6950e2
  42. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons. N Engl J Med. Published online April 21, 2021. doi:10.1056/NEJMoa2104983
  43.  Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Moderna COVID-19 vaccine – United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69(5152):1653-1656. doi:10.15585/mmwr.mm695152e1